Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Outcome for Outcome Of The Board Meeting Held On June 26, 2023.

 Based on the recommendations of the Nomination and Remuneration Committee of Board of Directors, have interalia discussed and approved the appointment of following directors: 1. Mr. Vinayak Dinesh Dendukuri (DIN: 07601309) as Additional Director designated as Whole-time Director - Operation. 2. Mr. Upendar Mekala Reddy (DIN: 08898174) as Additional Director designated as Non-Executive Non-independent Director; 3. Mr. Krishna Yeachuri (DIN: 00066898) as Additional Director designated as Non-Executive Independent Director.
27-06-2023
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for A Meeting Of The Board Of Directors Of Bafna Pharmaceuticals Limited Is Scheduled To Be Held On June 26, 2023.

 BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/06/2023 ,inter alia, to consider and approve inter alia, to consider and approve the appointment of 1. Mr. Vinayak Dinesh Dendukuri (DIN: 07601309) as Additional Director designated as Whole-time Director - Operation. 2. Mr. Upendar Mekala Reddy (DIN: 08898174) as Additional Director designated as Non-Executive Non-independent Director; 3. Mr. Krishna Yeachuri (DIN: 00066898) as Additional Director designated as Non-Executive Independent Director, and any other business with the permission of the Chair.
23-06-2023
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Compliances-Reg.24(A)-Annual Secretarial Compliance

 Annual Secretarial Compliance Report for the financial year 2022-2023.
30-05-2023
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Newspaper clippings of Audited Standalone Financial Results of the Company for the 4th quarter and year ended March 31, 2023, which was approved by the Board in its meeting held on May 27, 2023,
29-05-2023
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Audited Financial Results For The Year Ended March, 31 2023.

 We herewith submit the Audited Financial results (standalone) for the quarter and year ended March 31, 2023, which was approved by the Board Of Directors in the Meeting held on 27.05.2023
27-05-2023
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 27.05.2023

 We hereby inform you that the Board at its meeting held on May 27, 2023 had considered and approved the Audited Financial results for the quarter and year ended March 31, 2023.
27-05-2023
Bigul

Annual report for Bafna Pharmaceuticals Ltd. for FY-2023
27-05-2023
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Update on board meeting

 The Board Meeting to be held on 24/05/2023 has been revised to 27/05/2023 The Board Meeting to be held on 24/05/2023 has been rescheduled to 27/05/2023
22-05-2023
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for To Consider And Approve The Audited Financial Results Of The Company For The Quarter And Financial Year Ended 31 March 2023.

 BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2023 ,inter alia, to consider and approve the Audited Financial Results of the Company for the quarter and financial year ended 31 March 2023.
17-05-2023
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyBAFNA PHARMACEUTICALS LTD. 2CIN NO.L24294TN1995PLC030698 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY BB+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Vishnu Vasudeva Kuppa Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Melagiri Sridhar Designation: Chief Financial Officer EmailId: [email protected] Date: 05/05/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
05-05-2023
Next Page
Close

Let's Open Free Demat Account